Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Raffaele Califano, ESMO 2019 –  FLAURA study in NSCLC

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 22nd 2019

Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust)  joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125).

Questions
1.    Please describe the FLAURA trail and its reported results? (0:04)
2.    Clinically, what impact do you think osimertinib will have over existing standard of care for patients with NSCLC? (3:00)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Raffaele Califano has acted as a consultant and advisor for AstraZeneca and BMS.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup